Concepts (202)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreaticoduodenectomy | 6 | 2021 | 106 | 1.290 |
Why?
|
| Body Weight | 1 | 2024 | 994 | 0.630 |
Why?
|
| Bile Ducts, Intrahepatic | 3 | 2007 | 105 | 0.570 |
Why?
|
| Bile Duct Neoplasms | 3 | 2007 | 124 | 0.530 |
Why?
|
| Cholangiocarcinoma | 3 | 2007 | 123 | 0.530 |
Why?
|
| Hepatectomy | 3 | 2008 | 119 | 0.530 |
Why?
|
| Postoperative Complications | 8 | 2025 | 3142 | 0.520 |
Why?
|
| Pancreatectomy | 4 | 2025 | 149 | 0.510 |
Why?
|
| Anastomosis, Roux-en-Y | 1 | 2016 | 9 | 0.490 |
Why?
|
| Pylorus | 1 | 2016 | 21 | 0.490 |
Why?
|
| Drainage | 5 | 2019 | 264 | 0.480 |
Why?
|
| Gastric Emptying | 1 | 2016 | 79 | 0.480 |
Why?
|
| Jejunum | 1 | 2016 | 129 | 0.460 |
Why?
|
| Liver | 5 | 2011 | 1797 | 0.460 |
Why?
|
| Gastroparesis | 1 | 2016 | 67 | 0.450 |
Why?
|
| Liver Neoplasms | 7 | 2010 | 1381 | 0.450 |
Why?
|
| Liver Transplantation | 9 | 2011 | 1103 | 0.440 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2010 | 985 | 0.430 |
Why?
|
| Stomach | 1 | 2016 | 273 | 0.410 |
Why?
|
| Pancreatic Fistula | 2 | 2014 | 30 | 0.400 |
Why?
|
| Pancreaticojejunostomy | 1 | 2012 | 6 | 0.380 |
Why?
|
| Cyanoacrylates | 1 | 2012 | 12 | 0.380 |
Why?
|
| Obesity | 1 | 2024 | 2391 | 0.380 |
Why?
|
| Tissue Adhesives | 1 | 2012 | 39 | 0.370 |
Why?
|
| Cell Transplantation | 1 | 2011 | 42 | 0.360 |
Why?
|
| Hepatic Stellate Cells | 1 | 2011 | 27 | 0.360 |
Why?
|
| Ampulla of Vater | 1 | 2010 | 17 | 0.340 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2010 | 10 | 0.340 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2010 | 37 | 0.340 |
Why?
|
| Yttrium Radioisotopes | 5 | 2009 | 19 | 0.330 |
Why?
|
| Hepatocytes | 1 | 2011 | 237 | 0.320 |
Why?
|
| Tissue Engineering | 1 | 2011 | 168 | 0.320 |
Why?
|
| Tumor Burden | 1 | 2010 | 246 | 0.300 |
Why?
|
| Pilot Projects | 4 | 2016 | 1450 | 0.280 |
Why?
|
| Middle Aged | 20 | 2025 | 28964 | 0.270 |
Why?
|
| Jehovah's Witnesses | 1 | 2007 | 17 | 0.270 |
Why?
|
| Cyclosporine | 4 | 2002 | 126 | 0.260 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2007 | 88 | 0.260 |
Why?
|
| Perfusion | 1 | 2007 | 208 | 0.250 |
Why?
|
| Patient Selection | 1 | 2010 | 737 | 0.240 |
Why?
|
| Obesity, Morbid | 1 | 2008 | 210 | 0.240 |
Why?
|
| Quality of Life | 3 | 2025 | 2137 | 0.230 |
Why?
|
| Pancreatitis, Chronic | 1 | 2025 | 76 | 0.220 |
Why?
|
| Bahrain | 1 | 2024 | 3 | 0.220 |
Why?
|
| Postoperative Care | 2 | 2019 | 312 | 0.220 |
Why?
|
| Biomarkers, Tumor | 2 | 2021 | 1658 | 0.210 |
Why?
|
| Immunosuppressive Agents | 4 | 2002 | 672 | 0.200 |
Why?
|
| Clinical Decision-Making | 1 | 2025 | 307 | 0.190 |
Why?
|
| Female | 24 | 2025 | 70710 | 0.180 |
Why?
|
| Pancreatic Neoplasms | 2 | 2018 | 729 | 0.180 |
Why?
|
| Carcinosarcoma | 1 | 2021 | 12 | 0.170 |
Why?
|
| B7 Antigens | 1 | 2020 | 14 | 0.170 |
Why?
|
| Humans | 33 | 2025 | 132061 | 0.170 |
Why?
|
| Adult | 11 | 2025 | 31567 | 0.160 |
Why?
|
| Prospective Studies | 7 | 2019 | 6567 | 0.160 |
Why?
|
| Aged | 12 | 2025 | 21406 | 0.160 |
Why?
|
| Treatment Outcome | 11 | 2019 | 13028 | 0.150 |
Why?
|
| Tissue and Organ Procurement | 2 | 2010 | 246 | 0.150 |
Why?
|
| Male | 19 | 2025 | 64920 | 0.150 |
Why?
|
| Microspheres | 3 | 2009 | 73 | 0.150 |
Why?
|
| Neoplasm Staging | 4 | 2010 | 1356 | 0.150 |
Why?
|
| Body Mass Index | 1 | 2024 | 1694 | 0.140 |
Why?
|
| Prevalence | 1 | 2024 | 2658 | 0.130 |
Why?
|
| Surveys and Questionnaires | 2 | 2024 | 3990 | 0.130 |
Why?
|
| Radiopharmaceuticals | 2 | 2009 | 170 | 0.130 |
Why?
|
| Evidence-Based Practice | 1 | 2018 | 115 | 0.130 |
Why?
|
| Nutritional Support | 1 | 2017 | 55 | 0.130 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2018 | 169 | 0.130 |
Why?
|
| Metabolic Diseases | 2 | 2017 | 139 | 0.120 |
Why?
|
| Tissue Donors | 3 | 2000 | 504 | 0.120 |
Why?
|
| Pyloric Antrum | 1 | 2016 | 62 | 0.120 |
Why?
|
| Intestinal Mucosa | 1 | 2021 | 794 | 0.120 |
Why?
|
| Cross-Sectional Studies | 1 | 2024 | 3761 | 0.110 |
Why?
|
| Glucose | 2 | 2011 | 878 | 0.110 |
Why?
|
| Evidence-Based Medicine | 1 | 2019 | 662 | 0.110 |
Why?
|
| Angiography | 2 | 2005 | 209 | 0.110 |
Why?
|
| Length of Stay | 4 | 2014 | 1379 | 0.110 |
Why?
|
| Young Adult | 2 | 2024 | 9956 | 0.110 |
Why?
|
| Follow-Up Studies | 4 | 2017 | 5409 | 0.100 |
Why?
|
| Aged, 80 and over | 3 | 2016 | 7102 | 0.100 |
Why?
|
| Practice Patterns, Physicians' | 1 | 2019 | 768 | 0.100 |
Why?
|
| Diabetes Mellitus | 1 | 2020 | 921 | 0.090 |
Why?
|
| Administration, Topical | 1 | 2012 | 140 | 0.090 |
Why?
|
| Organ Transplantation | 1 | 1994 | 180 | 0.090 |
Why?
|
| Lactates | 1 | 2011 | 85 | 0.090 |
Why?
|
| Jejunostomy | 2 | 2009 | 22 | 0.090 |
Why?
|
| Coculture Techniques | 1 | 2011 | 235 | 0.090 |
Why?
|
| Transplantation, Heterologous | 1 | 2011 | 271 | 0.090 |
Why?
|
| Survival Rate | 4 | 2010 | 2192 | 0.080 |
Why?
|
| Cohort Studies | 3 | 2020 | 5164 | 0.080 |
Why?
|
| Patient Care Team | 1 | 1994 | 571 | 0.080 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2020 | 1408 | 0.080 |
Why?
|
| Resource Allocation | 1 | 2010 | 53 | 0.080 |
Why?
|
| Postoperative Period | 1 | 2010 | 335 | 0.080 |
Why?
|
| Risk Factors | 3 | 2019 | 10941 | 0.080 |
Why?
|
| Cell Survival | 1 | 2011 | 865 | 0.080 |
Why?
|
| Organ Preservation | 2 | 2003 | 53 | 0.070 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2010 | 822 | 0.070 |
Why?
|
| Reoperation | 1 | 2012 | 853 | 0.070 |
Why?
|
| Hepatic Artery | 2 | 2005 | 47 | 0.070 |
Why?
|
| Multivariate Analysis | 1 | 2012 | 1436 | 0.070 |
Why?
|
| Patient Readmission | 1 | 2012 | 425 | 0.070 |
Why?
|
| Radiography, Interventional | 2 | 2005 | 88 | 0.070 |
Why?
|
| Radiation Injuries | 1 | 2009 | 159 | 0.070 |
Why?
|
| Swine | 1 | 2011 | 1200 | 0.070 |
Why?
|
| Oxygen | 1 | 2011 | 572 | 0.070 |
Why?
|
| Hemodilution | 1 | 2007 | 14 | 0.070 |
Why?
|
| Prognosis | 2 | 2023 | 5009 | 0.070 |
Why?
|
| Procaine | 1 | 2007 | 12 | 0.070 |
Why?
|
| Tomography, Spiral Computed | 1 | 2007 | 15 | 0.070 |
Why?
|
| Potassium Chloride | 1 | 2007 | 48 | 0.070 |
Why?
|
| Mannitol | 1 | 2007 | 44 | 0.070 |
Why?
|
| Melphalan | 1 | 2007 | 46 | 0.070 |
Why?
|
| Biliary Tract Surgical Procedures | 1 | 2007 | 23 | 0.070 |
Why?
|
| Adolescent | 4 | 2024 | 20562 | 0.070 |
Why?
|
| Logistic Models | 1 | 2012 | 1838 | 0.070 |
Why?
|
| Adenocarcinoma | 2 | 2021 | 1014 | 0.070 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2010 | 1131 | 0.060 |
Why?
|
| Retrospective Studies | 6 | 2018 | 17419 | 0.060 |
Why?
|
| Vena Cava, Inferior | 1 | 2007 | 105 | 0.060 |
Why?
|
| Blood Loss, Surgical | 1 | 2007 | 159 | 0.060 |
Why?
|
| Gastritis | 1 | 2009 | 373 | 0.060 |
Why?
|
| Proportional Hazards Models | 1 | 2010 | 1454 | 0.060 |
Why?
|
| Hypothermia, Induced | 1 | 2007 | 170 | 0.060 |
Why?
|
| Doxorubicin | 1 | 2007 | 303 | 0.060 |
Why?
|
| Neoplasms | 1 | 2020 | 2955 | 0.060 |
Why?
|
| Cells, Cultured | 1 | 2011 | 3036 | 0.060 |
Why?
|
| Cisplatin | 1 | 2007 | 281 | 0.060 |
Why?
|
| Cell Proliferation | 1 | 2011 | 2508 | 0.050 |
Why?
|
| Immunoglobulin G | 1 | 2007 | 806 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 3 | 2009 | 2172 | 0.050 |
Why?
|
| Combined Modality Therapy | 1 | 2007 | 1294 | 0.050 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2010 | 1297 | 0.050 |
Why?
|
| Embolization, Therapeutic | 1 | 2005 | 223 | 0.050 |
Why?
|
| Liver Function Tests | 1 | 2002 | 102 | 0.050 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2018 | 1247 | 0.050 |
Why?
|
| Temperature | 1 | 2003 | 303 | 0.050 |
Why?
|
| Area Under Curve | 1 | 2002 | 321 | 0.050 |
Why?
|
| Registries | 2 | 2019 | 1572 | 0.040 |
Why?
|
| Drug Therapy, Combination | 2 | 2002 | 1180 | 0.040 |
Why?
|
| Drug Monitoring | 1 | 2002 | 174 | 0.040 |
Why?
|
| Regression Analysis | 1 | 2002 | 792 | 0.040 |
Why?
|
| Disease-Free Survival | 1 | 2023 | 955 | 0.040 |
Why?
|
| Enterocytes | 1 | 2021 | 75 | 0.040 |
Why?
|
| Time Factors | 2 | 2019 | 6448 | 0.040 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 257 | 0.040 |
Why?
|
| Amylases | 1 | 2019 | 24 | 0.040 |
Why?
|
| Incidence | 2 | 2019 | 3380 | 0.040 |
Why?
|
| Antigens, Neoplasm | 1 | 2020 | 401 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2018 | 166 | 0.040 |
Why?
|
| Injections, Intra-Arterial | 2 | 2009 | 18 | 0.030 |
Why?
|
| Non-Randomized Controlled Trials as Topic | 1 | 2017 | 13 | 0.030 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2018 | 391 | 0.030 |
Why?
|
| Immunohistochemistry | 1 | 2021 | 1694 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2000 | 504 | 0.030 |
Why?
|
| Pancreas | 1 | 2017 | 222 | 0.030 |
Why?
|
| Device Removal | 1 | 2018 | 227 | 0.030 |
Why?
|
| Immunotherapy | 1 | 2020 | 745 | 0.030 |
Why?
|
| Nutritional Status | 1 | 2017 | 294 | 0.030 |
Why?
|
| Radiotherapy Dosage | 2 | 2005 | 237 | 0.030 |
Why?
|
| Malnutrition | 1 | 2017 | 161 | 0.030 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 566 | 0.030 |
Why?
|
| Antibodies, Monoclonal | 1 | 2020 | 1028 | 0.030 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2014 | 18 | 0.030 |
Why?
|
| Liver Diseases | 1 | 1998 | 384 | 0.030 |
Why?
|
| Operating Rooms | 1 | 1994 | 79 | 0.030 |
Why?
|
| Brain Death | 1 | 1994 | 70 | 0.030 |
Why?
|
| Clinical Protocols | 1 | 1994 | 239 | 0.030 |
Why?
|
| Cell Differentiation | 1 | 2021 | 1960 | 0.020 |
Why?
|
| Survival Analysis | 2 | 2008 | 1573 | 0.020 |
Why?
|
| United States | 2 | 2020 | 11658 | 0.020 |
Why?
|
| Databases, Factual | 1 | 2017 | 1227 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2009 | 3833 | 0.020 |
Why?
|
| Biomarkers | 2 | 2017 | 3406 | 0.020 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2018 | 1342 | 0.020 |
Why?
|
| Animals | 1 | 2011 | 34881 | 0.020 |
Why?
|
| Gastroscopy | 1 | 2009 | 102 | 0.020 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 1824 | 0.020 |
Why?
|
| Emulsions | 2 | 1998 | 70 | 0.020 |
Why?
|
| Gastric Bypass | 1 | 2009 | 80 | 0.020 |
Why?
|
| Infusions, Intra-Arterial | 1 | 2008 | 27 | 0.020 |
Why?
|
| Tomography, Emission-Computed | 1 | 2008 | 37 | 0.020 |
Why?
|
| Enteral Nutrition | 1 | 2009 | 267 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2014 | 3091 | 0.010 |
Why?
|
| Chemoembolization, Therapeutic | 1 | 2005 | 27 | 0.010 |
Why?
|
| Hepatitis C | 1 | 2009 | 386 | 0.010 |
Why?
|
| Angiography, Digital Subtraction | 1 | 2005 | 51 | 0.010 |
Why?
|
| Bilirubin | 1 | 2003 | 128 | 0.010 |
Why?
|
| Age Distribution | 1 | 2003 | 437 | 0.010 |
Why?
|
| Disease Progression | 1 | 2008 | 2224 | 0.010 |
Why?
|
| Color | 1 | 2000 | 34 | 0.010 |
Why?
|
| Audiovisual Aids | 1 | 2000 | 24 | 0.010 |
Why?
|
| Tissue and Organ Harvesting | 1 | 2000 | 39 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 1998 | 247 | 0.010 |
Why?
|
| Living Donors | 1 | 1998 | 116 | 0.010 |
Why?
|
| Hospital Costs | 1 | 1998 | 187 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 1998 | 547 | 0.010 |
Why?
|
| Administration, Oral | 1 | 1998 | 698 | 0.010 |
Why?
|
| Cost-Benefit Analysis | 1 | 1998 | 576 | 0.010 |
Why?
|
| Child | 3 | 1998 | 25789 | 0.010 |
Why?
|
| Infant | 2 | 1998 | 13064 | 0.010 |
Why?
|
| Child, Preschool | 2 | 1998 | 14751 | 0.010 |
Why?
|